Treatment is essential, because HD chorea progressively limits people’s lives1

Nearly 90% of patients with Huntington’s disease (HD) develop chorea, which can be one of the early signs of HD and may cause significant functional impact.2,3

Patients may experience functional
impact on3:

Pen icon.

Fine and gross motor
functions

Person walking icon.

Gait and balance

Scale icon.

Ability to maintain weight


In a survey conducted by the Huntington’s Disease Society of America (HDSA) published in 2016, caregivers cited chorea as the most impactful symptom of HD4

HD chorea impact three icons. HD chorea impact three icons.

As HD chorea progresses, movements become more frequent, and appear throughout the body,
interfering with activities of daily living. Patients then become completely dependent on their
carepartners, who may become overwhelmed.1

By treating HD chorea early, you can make a difference in patients’ lives5,6

Most patients and carepartners state that it is “very important” to manage chorea; their concerns include loss of independence, unpredictability/uncontrollability, and impact on family life.

There are no data to suggest that AUSTEDO affects any of the outcomes presented above.


Management of chorea may be met with many challenges

There are a limited number of FDA-approved treatment options available for HD chorea.3,7

Limitations of tolerability3,7

  • Medications may have dose-limiting side effects. Treatment of chorea should be determined individually as a balance of chorea reduction and medication tolerability

Severity of chorea3

  • Chorea severity may vary over the course of the disease

Prevalence of depression and suicidality in HD

  • The lifetime prevalence of major depression in people with HD is about 40%8
  • Suicide rates range from approximately 5% to 13%9
  • 25% of patients attempt suicide10

Concomitant medications8

  • Some prescription medications may worsen voluntary motor control

Gray video icon

Watch as Eileen discusses how HD chorea has impacted her life, and in particular, her work

REFERENCES: 1. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40. 2. Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease. Drug Des Devel Ther. 2018;12:313-319. 3. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington’s Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington’s Disease Society of America; 2014. 4. Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395-403. 5. Beglinger LJ, O’Rourke JJF, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-418. 6. Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547-559. 7. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 8. Nance M, Paulsen J, Rosenblatt A, Wheelock V. 2011. A Physician’s Guide To The Management Of Huntington’s Disease. 3rd ed. New York: Huntington’s Disease Society of America. 9. Wetzel HH, Gehl CR, Dellefave-Castillo L, et al. Suicidal ideation in Huntington's disease: the role of comorbidity. Psychiatry Res. 2011;188(3):372-376. 10. Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease good clinical practice versus evidence-based approaches? Mov Disord. 2014;29(11):1404-1413. 11. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.